ReviewDermatology practical & conceptual2026
Stapokibart (CM310) in Atopic Dermatitis: A Narrative Review of a Next-Generation IL-4Rα Antagonist.
Review in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe interleukin (IL)-4/IL-13 signaling pathway is central to the pathogenesis of atopic dermatitis (AD). Stapokibart (CM310) is a novel humanized monoclonal antibody targeting the IL-4 receptor alpha (IL-4Rα) subunit.
objectiveTo summarize current evidence on the mechanism of action, clinical efficacy, safety, and therapeutic potential of stapokibart for moderate-to-severe AD.
methodsA narrative review was conducted based on a targeted search of PubMed/MEDLINE and ClinicalTrials.gov covering literature published from January 2015 to January 2026.
resultsStapokibart binds IL-4Rα with high affinity (KD = 0.25 nM), inhibiting downstream IL-4 and IL-13 signaling. In a phase 3 trial (N=500), stapokibart 300 mg every two weeks demonstrated significant improvements at Week 16, with 66.9% achieving EASI-75 (vs. 25.8% placebo) and 44.2% achieving IGA 0/1 (vs. 16.1% placebo; P<0.0001). Among responders, 92.5% maintained EASI-75 through Week 52. The treatment was generally well tolerated, with upper respiratory tract infections and injection-site reactions being the most common adverse events. Conjunctivitis occurred at low rates (5.0-5.9%).
conclusionsStapokibart shows robust efficacy and a favorable safety profile in adults with moderate-to-severe AD, including sustained long-term responses and low conjunctivitis rates. While early data are encouraging, all comparisons with existing IL-4/IL-13 inhibitors are indirect, and further global phase 3 studies and real-world evidence are needed to define its role within treatment algorithms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.